Technetium tc-99m depreotide - Generic Drug Details

What are the generic drug sources for technetium tc-99m depreotide and what is the scope of freedom to operate?

Technetium tc-99m depreotide is the generic ingredient in one branded drug marketed by Cis Bio Intl Sa and is included in one NDA. Additional information is available in the individual branded drug profile pages.

Summary for technetium tc-99m depreotide

US Patents:	0
Tradenames:	1
Applicants:	1
NDAs:	1
Raw Ingredient (Bulk) Api Vendors:	7
DailyMed Link:	technetium tc-99m depreotide at DailyMed

US Patents and Regulatory Information for technetium tc-99m depreotide

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Cis Bio Intl Sa	NEO TECT KIT	technetium tc-99m depreotide	INJECTABLE;INJECTION	021012-001	Aug 3, 1999		DISCN	No	No

Technetium Tc-99m Depreotide Market Dynamics, Patent Status, and Financial Trajectory

Last updated: September 20, 2026

Technetium Tc-99m depreotide, marketed as NeoTect, is a niche nuclear-medicine diagnostic agent used with planar scintigraphy or SPECT to evaluate pulmonary lesions suspected of malignancy. Its commercial trajectory peaked before widespread FDG-PET/CT adoption and then weakened as physicians and payers shifted toward metabolic imaging. No major public company reports NeoTect revenue as a material standalone product, and the product has limited commercial presence in the United States.

What is technetium Tc-99m depreotide used for?

Technetium Tc-99m depreotide is a radiolabeled somatostatin analog. The depreotide peptide binds somatostatin receptor subtypes, particularly receptors expressed on some malignant pulmonary lesions. Technetium-99m provides the imaging signal.

NeoTect was approved as an adjunct to standard diagnostic evaluation of pulmonary lesions suspected of malignancy. The product was not approved as a replacement for biopsy, CT, or other diagnostic procedures.

Attribute	Technetium Tc-99m depreotide
Brand	NeoTect
Active radiopharmaceutical	Technetium Tc-99m depreotide
Therapeutic category	Diagnostic nuclear medicine
Principal use	Imaging of suspected malignant pulmonary lesions
Administration	Intravenous
Imaging format	Scintigraphy and SPECT
Radiotracer half-life	Approximately six hours for Tc-99m
FDA pathway	New drug application
U.S. approval	2004, according to the product labeling
Commercial status	Limited or discontinued U.S. availability
Biosimilar exposure	None
Principal competitive technology	FDG-PET/CT

The short physical half-life of technetium-99m requires a coordinated supply chain involving generator or reactor supply, radiopharmacy preparation, quality control, and same-day administration. That structure limits inventory flexibility and increases dependence on hospital nuclear-medicine infrastructure (U.S. Food and Drug Administration [FDA], 2004).

When did NeoTect lose commercial momentum?

NeoTect entered a market already moving toward fluorodeoxyglucose positron-emission tomography, or FDG-PET. FDG-PET/CT offered whole-body metabolic imaging and became more integrated into lung-cancer staging pathways. This reduced the commercial role of receptor-targeted scintigraphy for indeterminate lung nodules.

The product’s market trajectory can be divided into four phases:

Period	Market condition	Commercial effect
Pre-2004	Development and regulatory review	Investment focused on validation and radiopharmacy distribution
2004-2008	Initial U.S. commercialization	Niche adoption in centers without broad PET access
2008-2015	Expansion of PET/CT	Pressure on utilization, reimbursement, and physician preference
After 2015	Limited commercial role	Product availability and revenue declined sharply

NeoTect’s commercial weakness was driven more by diagnostic substitution than by a classic generic-price collapse. The competing product was not another depreotide injection. It was a different imaging modality with broader staging utility.

What is the FDA regulatory status of technetium Tc-99m depreotide?

NeoTect received U.S. approval for use in evaluating pulmonary lesions in patients with an abnormal chest radiograph or CT scan. The label required use as part of a broader diagnostic workup.

The FDA-approved clinical evidence showed that depreotide imaging could contribute to the characterization of pulmonary lesions, but the test had imperfect sensitivity and specificity. The label reported performance that required confirmatory clinical assessment rather than autonomous diagnostic use (FDA, 2004).

FDA regulatory profile

Regulatory issue	Status
Approved indication	Adjunctive imaging of suspected malignant pulmonary lesions
Disease area	Lung cancer diagnosis and evaluation
Diagnostic limitation	False-positive and false-negative scans occur
Biologic classification	Not a biologic
Generic drug pathway	Potentially applicable in principle, but constrained by radiopharmaceutical manufacturing
Biosimilar pathway	Not applicable
Safety withdrawal	No widely documented safety-based withdrawal was the primary commercial issue
Current availability	Limited or absent in mainstream U.S. commercial channels

The distinction between FDA approval and commercial availability is important. An approved product may remain in FDA records while the sponsor no longer markets it at meaningful scale.

What patents protect technetium Tc-99m depreotide?

The original intellectual-property position likely covered the depreotide peptide, radiolabeling chemistry, diagnostic use, and kit or formulation architecture. Publicly available commercial information does not establish a currently enforceable, commercially significant U.S. patent barrier around NeoTect.

The relevant protection categories were:

1. Composition claims covering depreotide or related somatostatin analogs.
2. Radiolabeling claims covering technetium-99m complexes.
3. Method-of-use claims covering imaging of pulmonary malignancies.
4. Kit claims covering nonradioactive components used to prepare the injection.
5. Manufacturing and quality-control claims for radiopharmaceutical preparation.

Because technetium-99m decays rapidly, a patent on the active radiolabeled product has limited commercial value once the core peptide and preparation methods are no longer exclusive. The commercial barrier is often operational rather than legal.

Patent-expiration and exclusivity assessment

Protection type	Likely commercial relevance today
Core peptide composition	Likely expired or commercially weak
Radiolabeling chemistry	Potentially expired, nonexclusive, or avoidable
Pulmonary-lesion method of use	Limited value after market contraction
Kit formulation	Could protect a specific presentation, but does not necessarily block alternative kits
Manufacturing process	Relevant only if difficult to design around or supported by know-how
Regulatory exclusivity	Long expired
Orange Book patent exclusivity	No current high-value barrier is evident from the product’s market status

NeoTect’s FDA approval occurred in 2004. Any standard five-year new chemical entity exclusivity would have ended by 2009. Three-year approval-related exclusivity, if applicable to particular supplemental evidence, would not create a current barrier. Pediatric exclusivity is not a meaningful commercial factor for this product.

What is the Orange Book status of NeoTect?

NeoTect was approved under an NDA rather than an abbreviated generic application. The Orange Book can retain historical approval information even when a product is no longer actively marketed.

No current Orange Book listing is known to create a material blocking position for a prospective entrant. The practical questions for a competitor would be:

• Whether the reference NDA remains listed as approved.
• Whether any patent information remains listed.
• Whether the proposed product can rely on the reference product for an ANDA.
• Whether the radiopharmaceutical kit is sufficiently similar for an abbreviated pathway.
• Whether the product is commercially feasible despite the small addressable market.

A potential entrant would also need to address radioactive drug production, sterility, release testing, expiration dating, and distribution to radiopharmacies. Those requirements can be more important than conventional small-molecule patent rights.

Are there Paragraph IV challenges to technetium Tc-99m depreotide?

There is no prominent public record of a commercially consequential Paragraph IV campaign against NeoTect. That outcome is consistent with the product’s limited sales opportunity and the technical complexity of radiopharmaceutical substitution.

A Paragraph IV challenger would need to demonstrate that its proposed product is therapeutically equivalent or otherwise eligible for the relevant FDA pathway while managing:

• Short product dating.
• Radiochemical purity.
• Sterility and endotoxin limits.
• Technetium binding and labeling consistency.
• Dosimetry.
• Lot release timing.
• Regional radiopharmacy distribution.
• Limited clinical demand.

The absence of a major Paragraph IV dispute does not indicate strong patent protection. It more likely reflects weak expected returns from challenging a niche diagnostic product.

How strong is the patent estate for technetium Tc-99m depreotide?

The patent estate is commercially weak by current pharmaceutical standards.

Strengths

• The original product combined a defined peptide ligand with a specific radionuclide.
• Kit design and radiolabeling know-how could create manufacturing friction.
• A sponsor with established radiopharmacy distribution could limit practical competition.

Weaknesses

• Core exclusivity is old relative to the 2004 approval date.
• FDG-PET/CT reduced the value of method-of-use patents.
• A competitor could potentially design around specific kit or labeling claims.
• The product’s sales base appears too small to support extensive patent litigation.
• Short shelf life increases operating cost and reduces the value of centralized manufacturing rights.

The remaining defensibility is therefore more likely to reside in manufacturing controls, supplier relationships, regulatory know-how, and radiopharmacy logistics than in blocking patent claims.

What formulations and manufacturing processes are protected?

NeoTect was supplied as a kit for preparation of technetium Tc-99m depreotide injection. The kit format separated nonradioactive components from the radionuclide, allowing preparation at or near the clinical site.

Relevant technical protections can include:

• Peptide purity and impurity specifications.
• Lyophilized vial composition.
• Buffer system and stabilizers.
• Reducing agents required for technetium binding.
• Reaction time and temperature.
• Radiochemical purity.
• Sterility assurance.
• Container closure.
• Labeling and release testing.
• Stability during the short period between preparation and administration.

These elements can be difficult to reproduce at commercial scale, but they do not necessarily provide long-term exclusivity. A competitor can pursue an alternative kit architecture or an independently developed labeling process if it meets FDA quality requirements.

Which companies challenged or competed with NeoTect?

No major generic challenger became a defining competitive force in the U.S. market. The principal competitive pressure came from diagnostic alternatives and changes in clinical workflow.

Competitor or alternative	Competitive mechanism
FDG-PET/CT	Broader metabolic imaging and staging utility
Contrast-enhanced CT	Structural characterization and routine availability
Biopsy and pathology	Definitive tissue diagnosis
Other SPECT agents	Alternative nuclear-imaging approaches
Watchful imaging follow-up	Reduced immediate demand for specialized agents in selected patients

The competitive landscape favored products embedded in comprehensive cancer-imaging pathways. NeoTect’s narrower role made it vulnerable when PET/CT capacity expanded and reimbursement became more standardized.

What licensing deals affected technetium Tc-99m depreotide?

The product was associated with specialized radiopharmaceutical developers and commercial partners, including Diatide-related development and later commercial involvement by CIS Bio International and affiliated entities. Public disclosures do not support a current, material licensing stream tied to NeoTect.

The economic value of any original license would have depended on:

• Territory.
• Regulatory milestones.
• Manufacturing rights.
• Supply obligations.
• Royalty rates.
• Minimum purchase commitments.
• Rights to follow-on somatostatin-receptor products.

As the product declined, license economics would have weakened with utilization. The absence of visible current licensing activity is consistent with a product whose strategic value has diminished.

What is the financial trajectory of technetium Tc-99m depreotide?

NeoTect does not have a separately reported public revenue history comparable to a major branded pharmaceutical. The financial trajectory is therefore best assessed through market structure rather than reported annual sales.

Revenue trajectory

1. Initial revenue was supported by regulatory novelty and demand for noninvasive evaluation of suspicious pulmonary lesions.
2. Uptake remained limited because use depended on nuclear-medicine infrastructure and specialist referral patterns.
3. FDG-PET/CT reduced the number of cases in which depreotide offered a preferred diagnostic pathway.
4. Reimbursement and utilization pressure reduced repeat demand.
5. Commercial availability weakened as revenue no longer justified broad manufacturing and distribution.

Main cost drivers

• Peptide synthesis and purification.
• Kit production under sterile conditions.
• Technetium sourcing.
• Radiopharmacy distribution.
• Batch release testing.
• Regulatory maintenance.
• Small production runs.
• Inventory loss caused by radioactive decay.
• Sales and medical-support costs for a narrow indication.

The decay of Tc-99m creates a distinctive financial problem. Unsold radiopharmaceutical inventory loses value quickly, making demand forecasting and same-day distribution central to gross-margin performance.

What generic launch risks exist?

A generic or follow-on entrant would face a low patent risk but high market and execution risk.

Risk	Commercial impact
Small patient population	Limits achievable sales
PET/CT substitution	Reduces demand
Radiopharmacy complexity	Raises cost and operational risk
Short dating	Increases product waste
Limited reimbursement support	Restricts prescribing
Clinical inertia	Favors established diagnostic pathways
Reference-product availability	May complicate development and comparison
Manufacturing scale	Makes unit economics difficult

A successful entrant would need a lower-cost production model, dependable technetium access, regional radiopharmacy coverage, and a clear clinical niche not fully served by FDG-PET/CT.

How does technetium Tc-99m depreotide compare with FDG-PET/CT?

Metric	Tc-99m depreotide	FDG-PET/CT
Biological target	Somatostatin receptors	Glucose metabolism
Imaging platform	Scintigraphy/SPECT	PET combined with CT
Clinical scope	More focused pulmonary-lesion evaluation	Whole-body staging and lesion characterization
Supply model	Radiolabeled kit and nuclear pharmacy	Cyclotron or distributed FDG supply
Competitive position	Niche	Broad oncology adoption
Current commercial strength	Weak	Stronger and established
Patent relevance	Limited	More relevant across tracers, systems, and indications
Main substitution risk	High	Lower from depreotide

FDG-PET/CT had a stronger value proposition because it supported diagnosis, staging, treatment planning, and recurrence assessment across multiple cancers. NeoTect’s narrower utility made it less resilient to changes in imaging practice.

What patent litigation affects NeoTect?

No major ongoing patent litigation involving NeoTect is publicly associated with its current commercial position. There is no evident active dispute comparable to litigation surrounding high-revenue oncology medicines or biologic products.

The litigation risk profile is low because:

• Core market exclusivity is old.
• Revenue potential is limited.
• Alternative diagnostic modalities reduce the value of blocking claims.
• A successful injunction would have limited economic upside.
• Radiopharmaceutical manufacturing is difficult even without patent barriers.

Settlement agreements and Paragraph IV settlements also have no visible market significance for NeoTect.

What is the geographic coverage and international market position?

The product’s commercial relevance was concentrated in markets with established nuclear-medicine infrastructure. Geographic expansion was constrained by:

• Technetium supply.
• Local radiopharmacy requirements.
• National reimbursement policy.
• Availability of PET/CT.
• Regulatory requirements for radiopharmaceutical kits.
• Limited commercial demand.

Markets with broad PET/CT access had less need for depreotide. Markets with constrained PET availability could offer a theoretical niche, but the product still required specialized preparation and physician familiarity.

Key Takeaways

• Technetium Tc-99m depreotide, marketed as NeoTect, is a niche lung-lesion imaging agent rather than a therapeutic drug.
• The FDA approved NeoTect in 2004 as an adjunct to standard evaluation of suspected malignant pulmonary lesions.
• Its commercial decline was driven primarily by FDG-PET/CT substitution, not by a major generic price war.
• Regulatory exclusivity has long expired, and no current high-value Orange Book barrier is evident.
• Biosimilar competition is irrelevant because the product is not a biologic.
• Paragraph IV litigation and settlement activity have not materially shaped the market.
• Remaining defensibility lies mainly in radiopharmaceutical manufacturing, quality systems, and distribution.
• No separately reported public revenue stream supports a precise annual financial model.
• The product’s economic profile is constrained by a narrow indication, radioactive decay, small production runs, and limited clinical demand.

FAQs About Technetium Tc-99m Depreotide

Is technetium Tc-99m depreotide still sold in the United States?

NeoTect has limited or absent current U.S. commercial availability. Historical FDA approval should not be interpreted as evidence of active broad-market sales.

Is NeoTect a generic drug?

NeoTect was approved under an NDA. A follow-on applicant could face regulatory and manufacturing requirements distinct from those for conventional oral generics.

Does technetium Tc-99m depreotide have biosimilar competition?

No. Biosimilar rules apply to biological products, while depreotide is a radiolabeled peptide diagnostic agent.

Could a new radiopharmaceutical revive the depreotide market?

A revival would require a clinical advantage over FDG-PET/CT, improved reimbursement, dependable technetium supply, and a manufacturing model that avoids substantial radioactive inventory loss.

What is the main investment risk associated with NeoTect?

The main risk is market obsolescence. Even if manufacturing and patent barriers are manageable, a competitor using a broader imaging modality can reduce demand without directly copying the product.

References

1. U.S. Food and Drug Administration. (2004). NeoTect (technetium Tc 99m depreotide injection) prescribing information. FDA.

2. National Cancer Institute. (n.d.). Lung cancer diagnosis and staging. National Institutes of Health.

3. Centers for Medicare & Medicaid Services. (n.d.). Medicare coverage database: Positron emission tomography and nuclear medicine imaging. CMS.

4. Society of Nuclear Medicine and Molecular Imaging. (n.d.). SNMMI procedure standards for nuclear medicine imaging. SNMMI.

5. U.S. Food and Drug Administration. (n.d.). Approved drug products with therapeutic equivalence evaluations. FDA.